There are 3161 resources available
1286P - Explore-ALK (GFPC 03-2019): A real-world prospective, multicenter study of advanced ALK rearranged non-small cell lung cancer patients
Presenter: Chantal Decroisette
Session: Poster session 05
1287P - Predictive value of weight and BSA in assessing toxicity during ALK-TKIs in non-small cell lung cancer
Presenter: Beatriz Jimenez Munarriz
Session: Poster session 05
1288P - Clinical impact and landscape of heterogeneous ALK resistance mutations (muts) after comprehensive genomic profiling (CGP)
Presenter: Paul Hofman
Session: Poster session 05
1289P - Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)
Presenter: Maurice Pérol
Session: Poster session 05
1290P - Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC
Presenter: Matthew Krebs
Session: Poster session 05
1291P - Real-world treatment and overall survival (OS) in patients (pts) with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in England between 2014 and 2023
Presenter: Alastair Greystoke
Session: Poster session 05
1292P - A national real-world analysis of ROS1+ metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019)
Presenter: Gaelle Rousseau Bussac
Session: Poster session 05
1293P - Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial
Presenter: Ben Solomon
Session: Poster session 05
1294P - Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry
Presenter: Arianna Marinello
Session: Poster session 05
1295P - EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI
Presenter: Elena Garralda
Session: Poster session 05